EE279 Real-World Evidence Relating Cytopenia Diagnosis to Hospitalization and Cost of Care in the Treatment of Non-Small Cell Lung Cancer Patients

Abstract

Neutropenia is a driver of infection-related mortality in Non-Small Cell Lung Cancer (NSCLC) patients with chemotherapy-induced myelosuppression. Prior research found incident neutropenia in 24% of advanced NSCLC Medicare patients during first-line chemotherapy. Neutropenia-related care comprised up to one-third of total patient cost. We first confirmed the real-world incidence of cytopenia in an NSCLC population. Then we estimated the subsequent hospitalizations and total cost of care using OncoHealth Real-World Data (RWD). Our objective was to temporally sequence cytopenia diagnosis, hospitalization and accrual of costs to identify a window for targeting symptom management and patient engagement.